ACCU-CHEK CONNECT DIABETES MANAGEMENT APP
K141929 · Roche Diagnostics Corporation · NDC · Mar 16, 2015 · Anesthesiology
Device Facts
| Record ID | K141929 |
| Device Name | ACCU-CHEK CONNECT DIABETES MANAGEMENT APP |
| Applicant | Roche Diagnostics Corporation |
| Product Code | NDC · Anesthesiology |
| Decision Date | Mar 16, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 868.1890 |
| Device Class | Class 2 |
| Attributes | Software as a Medical Device, Therapeutic |
Intended Use
For Over-the-Counter Use: The ACCU-CHEK Connect Diabetes Management App is indicated as an aid in the treatment of diabetes. The software provides for electronic download of blood glucose meters, manual data entry, storage, display, transfer, and self-managing of blood glucose and other related health indicators which can be shown in report and graphical format. For Prescription Use: The ACCU-CHEK Bolus Advisor, as a component of the ACCU-CHEK Connect Diabetes Management App, is indicated for the management of diabetes by calculating an insulin dose or carbohydrate intake based on user-entered data. Before its use, a physician or healthcare professional must activate the bolus calculator and provide the patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the software.
Device Story
Mobile application for diabetes management; collects, transmits, and analyzes blood glucose data. Inputs: wireless data from ACCU-CHEK Aviva Connect blood glucose meter (via BLE) or manual user entry. Features: electronic logbook, report generation, and Bolus Advisor. Bolus Advisor transforms user-entered blood glucose, carbohydrate intake, and health event data into insulin dose recommendations using a pre-programmed, physician-configured algorithm. Used by patients with diabetes at home; HCPs configure bolus parameters. Output: graphical reports, insulin dose recommendations. Benefits: facilitates glycemic control, reduces fear of hypoglycemia, improves management confidence. App does not control insulin pumps or glucose meters.
Clinical Evidence
Non-clinical testing included software verification and algorithm validation. Human Factors clinical study confirmed the app met safety risk-mitigation requirements for patients and caregivers. No clinical efficacy trials reported.
Technological Characteristics
Mobile-based software application; connectivity via Bluetooth Low Energy (BLE) to compatible glucose meters. Software level of concern: Major. Algorithm: Rule-based bolus calculator.
Indications for Use
Indicated for diabetes patients undergoing multiple daily insulin injection (MDI) therapy. Bolus calculator component requires physician activation and programming of patient-specific parameters (target blood glucose, insulin-to-carbohydrate ratio, insulin sensitivity).
Regulatory Classification
Identification
A predictive pulmonary-function value calculator is a device used to calculate normal pulmonary-function values based on empirical equations.
Predicate Devices
- ACCU-CHEK Aviva Combo meter (K111353)
Related Devices
- K150910 — ACCU-CHEK Connect Diabetes Management App · Roche Diabetes Care, Inc. · Jun 3, 2015
- K202596 — Insulia Diabetes Management Companion · Voluntis Sa. · Jun 4, 2021
- K253512 — MiniMed Go App · Medtronic Minimed · Jan 8, 2026
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. The profiles are simple and abstract, with only the outlines of the faces visible.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 16. 2015
Roche Diagnostics Corporation Ms. Chunhong Tao Regulatory Affairs Specialist 9115 Hague Road Indianapolis, IN 46250
Re: K141929
Trade/Device Name: ACCU-CHEK Connect Diabetes Management App Regulation Number: 21 CFR 868.1890 Regulation Name: Drug Dosing Calculator Regulatory Class: II Product Code: NDC, LZG, LFR, JQP Dated: February 9, 2015 Received: February 12, 2015
Dear Ms. Tao:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Tina
Kiang -S
for Erin I. Keith, M.S. Division Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications for Use
510(k) Number (if known) K141929
Device Name
ACCU-CHEK Connect Diabetes Management App
#### Indications for Use (Describe)
The ACCU-CHEK Connect Diabetes Management App is indicated as an aid in the treatment of diabetes. The software provides for electronic download of blood glucose meters, manual data entry, storage, display, transfer, and self-managing of blood glucose and other related health indicators which can be shown in report and graphical format.
| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|--|
|-------------------------------------------------|--|
Prescription Use (Part 21 CFR 801 Subpart D)
|X | Over-The-Counter Use (21 CFR 801 Subpart C)
### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## Indications for Use
510(k) Number (if known) K141929
#### Device Name
ACCU-CHEK Connect Diabetes Management App
#### Indications for Use (Describe)
The ACCU-CHEK Bolus Advisor, as a component of the ACCU-CHEK Connect Diabetes Management App, is indicated for the management of diabetes by calculating an insulin dose or carbohydrate intake based on user-entered data. Before its use, a physician or healthcare professional must activate the bolus calculator and provide the patient-specific target blood glucose. insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the software.
| Type of Use (Select one or both, as applicable) | |
|------------------------------------------------------------------------------------------------|---------------------------------------------|
| <span style="text-decoration: underline;"></span> Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the Roche logo. The logo consists of the word "Roche" in bold, black letters, centered within a white hexagon. The hexagon is outlined in black. The logo is simple and recognizable.
# 510(k) Summary
| Introduction | According to the requirements of 21 CFR 807.92, the following information<br>provides sufficient detail to understand the basis for a determination of<br>substantial equivalence. | |
|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| 1) Submitter<br>name,<br>address,<br>contact | Primary contact: | Secondary contact: |
| | Mike Flis | Chunhong (Emma) Tao |
| | Roche Diagnostics Corporation | Roche Diagnostics Corporation |
| | 9115 Hague Rd. | 9115 Hague Rd. |
| | Indianapolis, IN 46250 | Indianapolis, IN 46250 |
| | (317) 521-2110 | (317) 521-7227 |
| 2) Device<br>name | Date Prepared: January 27, 2015 | |
| | Proprietary Name: ACCU-CHEK Connect Diabetes Management App<br>Common Name: diabetes management software | |
| | Primary<br>Classification Name: drug dosing calculator<br>Classification Regulation: 21 C.F.R. § 868.1890; Class II<br>Product Code: NDC | |
| | Secondary<br>Classification Name: calculator/data processing module for clinical use<br>Classification Regulations: 21 C.F.R. § 880.5725, 862.1345, 862.2100; Class II<br>Product Code: LZG, LFR, JQP | |
{5}------------------------------------------------
3) Predicate ACCU-CHEK Aviva Combo meter, cleared as a component of the ACCUdevice CHEK Combo System in #k111353.
The ACCU-CHEK Combo System consists of three (3) main components:
- . ACCU-CHEK Aviva Combo blood glucose meter
- . ACCU-CHEK Spirit Combo insulin pump
- ACCU-CHEK 360° Insulin Pump Configuration Software .
The ACCU-CHEK Aviva Combo meter serves as a hub for the ACCU-CHEK Combo System. The monitor has three main functions:
- . Blood glucose monitor
- Remote control of ACCU-CHEK Spirit Combo insulin pump .
- Calculation of insulin bolus י
The ACCU-CHEK Aviva Combo blood glucose meter is intended for the quantitative measurement of blood glucose. The ACCU-CHEK Aviva Combo meter is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitoring the effectiveness of diabetes control. The ACCU-CHEK Aviva Combo meter can be used to interface with and remotely control the ACCU-CHEK Spirit Combo insulin infusion pumps via radio frequency communication. The ACCU-CHEK Aviva Combo meter is also indicated for the management of diabetes by calculating an insulin dose or carbohydrate intake based on user-entered data.
Continued on next page
{6}------------------------------------------------
| 4) Device<br>Description | The ACCU-CHEK Connect Diabetes Management App is designed to<br>facilitate efficient collecting, transmitting, and analyzing of blood glucose<br>results and other diabetes management data. The App helps:<br><br>• Wireless transfer of data from ACCU-CHEK Aviva Connect Blood<br>Glucose Meter.<br>• Assist in general diabetes management through logging of contextual<br>data.<br>• ACCU-CHEK Bolus Advisor support of mealtime insulin dosing<br>calculations.<br>• Perform structured testing.<br>• Wireless transfer of data from mobile devices to ACCU-CHEK<br>Connect Online Diabetes Management System and optionally share<br>this data with healthcare provider (HCP) or caregiver.<br><br>The insulin bolus calculations provided by the app are meant for patients<br>undergoing multiple daily injection therapy. Bolus calculators, such as the<br>ACCU-CHEK Bolus Advisor, have been demonstrated to facilitate the<br>optimization of glycemic control in patients who are trained in multiple daily insulin injection therapy and under the supervision of healthcare professional |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5) Intended<br>use | For Over-the-Counter Use:<br>The ACCU-CHEK Connect Diabetes Management App is indicated as an aid<br>in the treatment of diabetes. The software provides for electronic download<br>of blood glucose meters, manual data entry, storage, display, transfer, and<br>self-managing of blood glucose and other related health indicators which can<br>be shown in report and graphical format. |
| | For Prescription Use:<br>The ACCU-CHEK Bolus Advisor, as a component of the ACCU-CHEK<br>Connect Diabetes Management App, is indicated for the management of<br>diabetes by calculating an insulin dose or carbohydrate intake based on user-<br>entered data. Before its use, a physician or healthcare professional must<br>activate the bolus calculator and provide the patient-specific target blood<br>glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be<br>programmed into the software. |
| 6) Substantial<br>equivalence | The ACCU-CHEK Connect Diabetes Management App utilizes the<br>processing power of a mobile phone operating system platform to transfer<br>data from a blood glucose meter, transfer data to an online diabetes<br>management system, facilitate structured testing data collection, assist in<br>general diabetes management through logging of contextual data, and<br>calculate insulin bolus in response to blood glucose, health events, and<br>carbohydrate input. These software functions were built within the predicate<br>device's embedded software and PC-platform software. The App moves<br>these functions outside the glucose meter. The App is compatible with<br>glucose meters with BLE transmitter. The insulin bolus calculator algorithm<br>is unchanged as compared to the predicate device. The App will not interact<br>with an insulin pump. The insulin bolus calculations provided by the App are<br>meant for patients undergoing conventional multiple daily injection therapy.<br>The ACCU-CHEK Connect Diabetes Management App is substantially |
| | equivalent to the drug dosage calculator function of the ACCU-CHEK Aviva<br>Combo meter.<br>Continued on next page |
experienced in managing insulin-treated patients. Such calculators have also been shown to reduce patient fear of hypoglycemia and improve patient confidence in diabetes management.
The ACCU-CHEK Connect Diabetes Management App is not intended to serve as an accessory to an insulin pump.
Continued on next page
{7}------------------------------------------------
{8}------------------------------------------------
### 7) Data demonstrating substantial equivalence
All necessary performance testing was conducted on the ACCU-CHEK Connect Diabetes Management App to support a determination of substantial equivalence. The results of usability testing of representative users of the device, software testing and performance testing of the device demonstrate the device functions as intended. The non-clinical testing included software verification and algorithm validation to demonstrate the functionality of the software application and the performance of the algorithms. The Human Factors clinical study demonstrated the diabetes management app fulfilled all predefined requirements for safety risk-mitigating controls when handled by persons with diabetes mellitus or their caregivers, according to its intended use.
Performance testing on the ACCU-CHEK Connect Diabetes Management App demonstrated that the device meets the performance requirements for its intended use. The data demonstrate that the device is substantially equivalent to the predicate device.
Continued on next page
{9}------------------------------------------------
| 8) | The following is a listing of the key similarities and differences between the |
|---------------|--------------------------------------------------------------------------------|
| Similarities/ | ACCU-CHEK Connect Diabetes Management App and the predicate device. |
| Differences | |
| Feature /Claim | ACCU-CHEK Connect Diabetes<br>Management App | ACCU-CHEK Combo System<br>(#k111353) |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | The ACCU-CHEK Connect<br>Diabetes Management App is<br>indicated as an aid in the treatment<br>of diabetes. The software provides<br>for electronic download of blood<br>glucose meters, manual data entry,<br>storage, display, transfer, and self-<br>managing of blood glucose and<br>other related health indicators which<br>can be shown in report and<br>graphical format.<br>The ACCU-CHEK Bolus Advisor,<br>as a component of the ACCU-<br>CHEK Connect Diabetes<br>Management App, is indicated for<br>the management of diabetes by<br>calculating an insulin dose or<br>carbohydrate intake based on user-<br>entered data. Before its use, a<br>physician or healthcare professional<br>must activate the bolus calculator<br>and provide the patient-specific<br>target blood glucose, insulin-to-<br>carbohydrate ratio, and insulin<br>sensitivity parameters to be<br>programmed into the software. | The ACCU-CHEK Aviva Combo<br>blood glucose meter is intended for<br>the quantitative measurement of<br>blood glucose. The ACCU-CHEK<br>Aviva Combo meter is intended for<br>self-testing outside the body (in<br>vitro diagnostic use) by people with<br>diabetes at home as an aid to<br>monitoring the effectiveness of<br>diabetes control. The ACCU-<br>CHEK Aviva Combo meter can be<br>used to interface with and remotely<br>control the ACCU-CHEK Spirit<br>Combo insulin infusion pumps via<br>radio frequency communication.<br>The ACCU-CHEK Aviva Combo<br>meter is also indicated for the<br>management of diabetes by<br>calculating an insulin dose or<br>carbohydrate intake based on user-<br>entered data. |
| Prescription /<br>over-the-counter<br>use? | Over-the-counter distribution of<br>App, with bolus calculator function<br>disabled until activated by physician | Prescription use due to relationship<br>with insulin pump |
| User Group | Diabetes patients treated with<br>multiple daily insulin injection<br>(MDI) therapy | Diabetes patients treated with<br>insulin pump therapy or multiple<br>daily insulin injection (MDI)<br>therapy |
| Bolus Calculator<br>Set-up stage | During the ACCU-CHEK Connect<br>Diabetes Management App's bolus<br>calculator set-up stage, the<br>following information must be | No difference, the same information<br>is inputted into the ACCU-CHEK<br>Combo meter during the bolus |
| Feature /Claim | ACCU-CHEK Connect Diabetes<br>Management App | ACCU-CHEK Combo System<br>(#k111353) |
| entered.<br>Time Blocks<br>Target Range<br>Carb Ratio<br>Insulin Sensitivity<br>Health Event Percentages<br>Meal Rise<br>Snack Size<br>Acting Time<br>Offset Time | calculator set-up stage. | |
| Bolus Calculator<br>inputs | Once the set-up stage has been<br>completed, the patient may begin<br>using the ACCU-CHEK Bolus<br>Advisor in the ACCU-CHEK<br>Connect Diabetes Management<br>App. Bolus recommendations can<br>be triggered by inputting the<br>following information prior to each<br>meal:<br>Measure blood glucose<br>Enter carbohydrates<br>Enter Health Event | No difference, the same information<br>is inputted by the patient prior to<br>each meal to trigger a<br>recommendation. |
| Communicate<br>with insulin<br>pumps? | No | Yes |
| Software Level of<br>Concern | Major | Major |
| Operating<br>platform | Mobile based application | Built within the blood glucose meter |
| Connectivity to<br>Meter | Bluetooth Low Energy (BLE) | N/A |
| Control or affect<br>the blood glucose<br>meter's<br>measurements? | No | No |
| Reports, graphs,<br>and Electronic<br>Log Book | Yes | No |
| Carbohydrate<br>Calculator | Calculate carbohydrate intake based<br>on user-entered data | Calculate carbohydrate intake based<br>on user-entered data |
| Feature /Claim | ACCU-CHEK Connect Diabetes<br>Management App | ACCU-CHEK Combo System<br>(#k111353) |
| Bolus Calculator | Yes | Yes |
| Bolus Calculator<br>Security | Bolus calculator function is<br>controlled as a prescription device;<br>the bolus calculator must be<br>activated by licensed healthcare<br>provider. Access to the bolus<br>calculator function requires licensed<br>healthcare provider activation. | The bolus calculator software is<br>embedded within a prescription<br>device. |
| Allow manual<br>entry? | Yes | No |
| Back-calculation<br>prevents insulin<br>stacking? | Yes | Yes |
{10}------------------------------------------------
{11}------------------------------------------------